drugset / Trial / NCT04028440
γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)
Phase 0
Unknown
6 enrolled
Institute of Hematology & Blood Diseases Hospital, China
Beijing GD Initiative Cell Therapy Technology Co., Ltd. · collabChinese Academy of Medical Sciences · collab
NaSingle-groupOpen-labelTreatment
Summary
This study aims to evaluate the safety and efficacy of autologous γδT cells in patients with relapsed or refractory B cell non-Hodgkin's lymphoma (B-NHL), chronic lymphoblastic leukemia (CLL) and peripheral T cell lymphoma (PTCL) expect for γδT lymphoma.
Timeline
- Start
- 2019-10
- Primary completion
- 2020-12-31
- Completion
- 2022-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Autologous γδT cells | Cell therapy | 1e+09 cells | Intravenous |
| Subject | Autologous γδT cells | Cell therapy | 2e+09 cells | Intravenous |